康寧傑瑞製藥(09966.HK)發布藥物KN046之最新臨床數據
康寧傑瑞製藥(09966.HK)公布,有關KN046(一種重組人源化PD-L1/CTLA-4雙特異性抗體)治療晚期NSCLC患者的II期臨床研究的臨床數據及KN046治療罕見胸部腫瘤患者的I期臨床研究的初步安全性及療效結果的摘要已獲准於即將舉行的2020年世界肺癌大會(WCLC 2020)上展示。
KN046治療晚期NSCLC患者的II期臨床研究的臨床數據顯示,其具有良好的耐受性,用於晚期NSCLC的二線治療有效,在NSCLC中顯示出PFS及OS獲益。而KN046治療罕見胸部腫瘤患者上具有良好的安全性,並與其他免疫檢查點抑制劑一致。KN046已初步顯示出良好療效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.